# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Phase 2b study demonstrated topical Sildenafil Cream, 3.6% improved outcomes among women with female sexual arousal disorder (F...
Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe men...
HC Wainwright & Co. analyst Douglas Tsao reiterates Dare Bioscience (NASDAQ:DARE) with a Buy and maintains $6 price target.
Brookline Capital analyst Kemp Dolliver upgrades Dare Bioscience (NASDAQ:DARE) from Hold to Buy and announces $3 price target.
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0...
-SEC Filing